Latest news
NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)
Read more
The power of precision.
For every cancer patient.
Today.
Press releases & news
-
NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)
Read more -
KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)
Read more -
2cureX announces final results regarding 2022 goals
Read more -
2cureX reaches 2022 geographic rollout goal of 20 countries
Read more
Latest report
Share Information
See our latest share informationCalendar & upcoming events
-
All things permitting, we look forward to seeing you all at ESMO GI again this summer. We will be there in Barcelona in person from 28 June – 1 July. More details to follow.
Go to event -
2cureX will attend (and co-sponsor) the Translational and Precision GI-Oncology – Freiburg Bench to Bedside Meeting.
Contact us for more -
2cureX will participate at the Swiss Nordic Bio 2023
Go to event -
2cureX will be attending and presenting at the Life Science Investor Conference in Copenhagen on 22 February.
Click here for more information
CEO Blog
Each month, 2cureX CEO Fernando Andreu reflects on developments in functional drug sensitivity testing, adjacent and complementary industries, our own developments, and the most interesting news in the press.
Subscribe to our newsletter at the bottom of the page.
More
Information for Oncologists and Pathologists
Know more when it matters most:
With our IndiTreat® tests you can finally obtain personalised information, even on the classic compounds for the main chemotherapy backbone for your stage IV mCRC patients.
Information for Patients
You’ve been diagnosed with colorectal cancer, and it is in stage IV. There are rational treatment choices to be made. Which therapy is more likely to impact the tumor? Ask your doctor about IndiTreat®.
More
A paradigm shift in cancer treatment
2cureX is introducing a new way in which treatment decisions are made. In this article, Raphael Gruber, our Medical Director talks about this paradigm shift in cancer treatment decisions.
MoreMedical Digests and News from the Scientific Community
Medical Digests
Each month, our Medical Director Raphael Gruber analyses and discusses new findings in a medical digest.
More
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations
More